UTHR

Rating neutralAI Memo

United Therapeutics

As of 2026-08-17/Confidence high

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-17 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

high

Horizon

—

Key catalyst

Potential nebulized Tyvaso approval in IPF • 2027-12-31

Base target: $540 / p=50% prob

Biggest risk

Near-term revenue and legacy-product declines indicate competitive and mix pressure. Approval timing is uncertain, management did not reaffirm detailed Tyvaso second-half targets in stored earnings commentary, and margin pressure or weaker physician adoption could delay the growth inflection.

Invalidation

Break below $425 or thesis failure.

What would change my mind?

UTHR has multiple potentially material cardiopulmonary expansion paths, including nebulized Tyvaso in IPF and ralinepag tablets in PAH, while Tyvaso DPI patient metrics remain strong. Stored earnings context also reported modest revenue and adjusted-EPS beats, though the source is secondary.

Research note

Recommendation

neutral

Confidence

high

As of

2026-08-17

Base target

$540

p=50%

Bull target

$650

p=25%

Bear target

$425

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Mixed Q2 execution keeps near-term expectations restrained
Tyvaso DPI commercial uptake
UTHR has multiple potentially material cardiopulmonary expansion paths, including nebulized Tyvaso in IPF and ralinepag tablets in PAH, while Tyvaso DPI patient metrics remain strong.

BearKey bullets

CEO Form 4 filings show multiple open-market sales on 2026-08-13 following an option exercise; this is insider-activity context, not evidence of operating performance [#SEC-FORM4-2026-08-14].
Competitive pressure in inhaled prostacyclins could continue to offset Tyvaso DPI growth.
FDA review, approval timing, and label-expansion execution for nebulized Tyvaso and ralinepag remain uncertain.

WatchKey bullets

Potential nebulized Tyvaso approval in IPF

Summary

High-level snapshot

Recommendation

neutral

Model confidence

high

Timeframe

Asset

Equity

Trigger

Base case: $540 (p=50%)

Target spread vs base: +20% / -21%

Scenario probabilities

Bull Target: $650 (p=25%)Base Target: $540 (p=50%)Bear Target: $425 (p=25%)

Commentary

News tone is mixed: Q2 EPS modestly exceeded estimates in stored earnings context, but revenue declined and core product trends weakened. The same stored context described an initially muted price reaction near the pre-earnings level. Social, options, short-interest, employee-review, and post-print analyst-revision data are unavailable, so this remains a moderate-confidence execution and regulatory monitoring setup.

As of 2026-08-17 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Mixed Q2 execution keeps near-term expectations restrained
Tyvaso DPI commercial uptake

Scenarios

Bull Target (Scenario probability)

$650 / p=25% prob

Base Target (Scenario probability)

$540 / p=50% prob

Bear Target (Scenario probability)

$425 / p=25% prob

Analysis 2026-08-17 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

52.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2027-12-31
Potential nebulized Tyvaso approval in IPF
United Therapeutics reported submission of an NDA for nebulized Tyvaso in IPF and described potential approval in 2027 as a major growth catalyst. Regulatory timing and approval outcome remain uncertain [#SEC-8K-2026-08-05].
Prob 55.00% • Move 12.00% • Priced-in 60.00%
EVENT2027-12-31
Potential ralinepag tablet approval in PAH
Management reported submission of an NDA for ralinepag tablets in PAH and identified potential 2027 approval as another transformative growth opportunity [#SEC-8K-2026-08-05].
Prob 50.00% • Move 10.00% • Priced-in 50.00%

Short-term Catalysts

Next few weeks

Mixed Q2 execution keeps near-term expectations restrained
2026-08-05
Q2 revenue declined 2% year over year to $783.3 million. Tyvaso DPI grew 4%, but nebulized Tyvaso declined 18%, total Tyvaso declined 4%, and Remodulin declined 6%, creating an execution and product-mix overhang [#SEC-8K-2026-08-05].
Prob 100% • Move -3% • Priced-in 85%

Long-term Catalysts

Months to a year

Tyvaso DPI commercial uptake
2026-12-31
Management reported record Tyvaso DPI starts, referrals, commercial patients, and total patients at quarter-end, supporting a possible return to sequential portfolio growth if physician adoption continues [#SEC-8K-2026-08-05].
Prob 65% • Move 8% • Priced-in 55%

Risks

CEO Form 4 filings show multiple open-market sales on 2026-08-13 following an option exercise; this is insider-activity context, not evidence of operating performance [#SEC-FORM4-2026-08-14].
Competitive pressure in inhaled prostacyclins could continue to offset Tyvaso DPI growth.
FDA review, approval timing, and label-expansion execution for nebulized Tyvaso and ralinepag remain uncertain.
Nebulized Tyvaso and Remodulin revenue declines may persist, delaying sequential portfolio growth.
Operating performance and product mix may remain under pressure if new-product adoption does not accelerate.

Peers

Symbol	Summary
REGN	Larger commercial-stage biopharma comparator for execution and pipeline optionality; indication overlap with UTHR is limited.
INCY	Similarly sized commercial biopharma comparator useful for execution-sensitive valuation, though not a direct PAH or IPF peer.
GILD	Large commercial biopharma benchmark for portfolio durability and cash generation; scale and portfolio mix make it a loose comparator.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-17

Loading AI feed…

Symbol

Summary

REGN

Larger commercial-stage biopharma comparator for execution and pipeline optionality; indication overlap with UTHR is limited.

INCY

Similarly sized commercial biopharma comparator useful for execution-sensitive valuation, though not a direct PAH or IPF peer.

GILD

Large commercial biopharma benchmark for portfolio durability and cash generation; scale and portfolio mix make it a loose comparator.